

aThis Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

EP 0 598 309 B1

(12)

EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention
of the grant of the patent:
28.01.1998 Bulletin 1998/05

(51) Int. Cl.⁶: **A61K 9/24**, **A61K 9/20**,
A61K 9/48

(21) Application number: 93118126.7

(22) Date of filing: 09.11.1993

(54) Multilayer matrix systems for the controlled release of active principles

Mehrschichtige Matrixsysteme mit kontrollierter Wirkstoffabgabe

Systèmes matriciels multicouches à libération contrôlée des agents actifs

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL
PT SE

(30) Priority: 17.11.1992 IT MI922617

(43) Date of publication of application:
25.05.1994 Bulletin 1994/21

(73) Proprietor:
INVERNI DELLA BEFFA S.P.A.
I-20141 Milano (IT)

(72) Inventors:
• Colombo, Paolo
Via Ripamonti 99 20141 Milano (IT)
• Corvi Cardona, Antonio
Via Ripamonti 99 20141 Milano (IT)

• Pifferi, Giorgio
I-20141 Milano (IT)

(74) Representative:
Blanchetti, Giuseppe
Studio Consulenza Brevettuale,
Via Rossini, 8
20122 Milano (IT)

(56) References cited:
EP-A- 0 432 607 GB-A- 2 203 338
US-A- 3 317 394

• JOURNAL OF PHARMACEUTICAL SCIENCES
vol. 82, no. 7, July 1993, WASHINGTON (US)
pages 750 - 754 XP369952 R.A. FASSIHI ET AL.
'multiple-layer, direct-compression, controlled-
release system: in vitro and in vivo evaluation'

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 598 309 B1

Description

Monolithic systems for the controlled release of drugs administered orally, are widely used both in human and veterinary therapy. The most widely used monolithic systems are matrix systems consisting of polymeric supports of more or less hydrophilic nature, within which the active principles are dissolved or dispersed. The geometry of these matrices, prepared by compression, and the structural characteristics of the polymers used, control the release of the active principles.

In the case of matrices consisting of a swelling hydrophilic polymer, the penetration of the dissolution fluid into the system gives rise to a polymer phase transition from glassy to rubbery state. This transition implies a distension of the polymeric chains which acquire great mobility and the formation of an increasing layer of gelled polymer. Diffusion of the active principle molecules takes place through the gelled layer, whereas this does not occur in the glassy state. The release kinetic of this matrix system is mainly related to diffusion, besides swelling and erosion. In most cases, release rate is a function of the square root of time and therefore tends to decrease as the thickness of the gelled polymeric layer and hence the thickness of the layer that the drug must cross in order to reach the dissolution fluid, increases with the time. A remarkable increase of the external surface of the system occurs because of the swelling and this effect contributes to increase the release rate. Nevertheless the overall observed result is a decreased drug release rate, more and more significant as the end of the release process is approached because of the prevailing effect of the increasing thickness of the gelled layer with the time.

Conventional matrix systems release the active principle more slowly and at a decreasing rate. They consequently do not overcome the disadvantages of traditional pharmaceutical forms, such as a peak of haematic concentration, followed by a relatively sudden fall.

There have been attempts to overcome these drawbacks, which are typical of hydrophilic matrices and related to a non-linear release kinetic. For example, in US Patent No. 4,839,177, a system is described which consists of a nucleus containing the drug and swelling polymer, having a defined shape, with an insoluble coating on one or more of its faces. The purpose of the coating is to modulate the swelling of the polymer so as to obtain a constant drug release. The system releases the drug with a constant kinetic only in cases where a base or the lateral surface are coated so as to delimit the releasing area. Moreover, the linear kinetic release is obtained only by using soluble polymers.

EP-A-0 432607 discloses a device for constant release of a drug comprising a core which swells on contact with water and a layer partly covering said core comprising slowly soluble and/or slowly gellable polymers.

The systems of the present invention allow the release of active principle at a constant rate, thanks to a geometry that varies during the release process. During the dissolution, the geometrical modifications of the claimed system are such as to determine a further and gradual increase in total release surface which compensates the reduction of release rate caused by the increase of gelled layer thickness.

Thanks to this system, it is possible to release one or more active principles contained in the monolithic system with a zero order kinetic, such as to maintain constant haematic concentrations.

According to a first preferred aspect, the invention gives three-layer monolithic systems consisting of two external swelling layers separated by an interposed soluble layer.

According to another preferred aspect, the invention gives two-layer monolithic systems consisting of a swelling layer adjacent to a soluble and/or erodible layer.

Examples of hydrophilic swelling polymers which can be used according to the invention include: methylcellulose, carboxymethylcellulose sodium, crosslinked carboxymethylcellulose sodium, crosslinked hydroxypropylcellulose, high, medium and low molecular weight, hydroxy-propyl methylcellulose, carboxymethyl starch, polymethacrylate, polyvinylpyrrolidone (crosslinked or not), high, medium and low molecular weight, polyvinyl alcohols, polyoxyethylene glycols, potassium methacrylate-divinyl benzene copolymer and their mixtures, in proportions between 5% and 70% by weight.

On the other hand, the soluble and/or erodible layer consists in soluble excipients, such as saccharides and polyalcohols, sometimes mixed with polymers selected from hydroxyethylcellulose, carboxymethylcellulose, alginates, albumin, soluble starch and gelatin in proportions up to 20% by weight.

Clearly, other excipients conventionally employed in pharmaceutical technology can be included in the monolithic systems of the invention, such as buffering agents, preservatives, lubricants and acid, basic or amphoteric substances. Examples of these excipients include spray-dried lactose, mannitol or other polyalcohols, talc and magnesium stearate or other lubricants. Active principles can be present in each layer in weight proportions according to their specific activity.

Monolithic systems of the invention can be prepared using conventional techniques, for example by simultaneous compression of the layers or by joining together two or more layers which have been individually prepared.

The invention will now be described with reference to the attached Figures, where:

Figure 1a shows a cross section of a three-layer monolithic system in which the upper, central and lower layers are marked by the

- letters U, C and L respectively;
- Figure 1b shows a cross section of a two-layer monolithic system in which the upper and lower layers are marked by the letters U and L respectively;
- Figure 2 shows a schematic drawing of the evolution of the system of in Figure 1a during the release process;
- Figure 3 shows a schematic drawing of the evolution of the system of Figure 1b during the release process;
- Figure 4 illustrates the release profiles of the systems described in Example 1;
- Figure 5 illustrates the release profiles of the systems described in Example 2;
- Figure 6 illustrates the release profiles of the systems described in Example 3.

Both in the cases of Figure 1a and Figure 1b, each layer consists of a polymer which can include the active principle to be released and/or other excipients with the function of controlling the release.

In the case of Figure 1a, layers U and L consist in a mixture containing a hydrophilic polymer and the active substance(s). On the other hand, layer C consists in a mixture of a soluble and/or erodible polymer, or a soluble excipient, in which an active principle may be added if desired.

Placing one of these systems in contact with the aqueous dissolution medium, the U and L layers, consisting of hydrophilic, swelling polymer, take up water to form a growing layer of gel and the system swells. In this way, the drug can be released with a mainly diffusive but also partly convective mechanism, governed by the distension of the polymeric chains. At the same time the C layer begins to disappear by dissolution and/or erosion.

The progressive disappearance of the central C layer brings about an increase in the surface of the external gelled layers exposed to solvent action, an increase added to that caused by the swelling of the U and L layers.

The decrease of the release rate with time, due to the increased thickness of the gelled layer of the U and L layers, is therefore compensated by the fact that the erosion and/or dissolution of the C layer brings about an increase in the releasing area, allowing contact of the solvent with the internal surfaces of the U and L layers. After a certain period of time, mostly related to the composition of the C layer, the separation of the U and L layers takes place.

A schematic drawing of the system evolution during the release process is shown in Figure 2, where the release area increases in time as a result of the disappearance of the C layer.

Therefore, the main aspect of this invention is that the C layer plays the role of controller of the release of active principles incorporated in the U and L layers. If another active principle is previously included in the C

layer, its release is controlled by the erosion and/or dissolution of the layer itself. This system, characterized by remarkable flexibility, allows a wide range of applications in order to obtain suitable release kinetic in the following cases:

- a) one active substance subdivided between the U and L layers;
- b) two active substances, one subdivided between the U and L layers and the other one incorporated in the C layer, or alternatively, one in the U and the other one in the L layer;
- c) three active substances, one in each layer.

By suitably adjusting the polymer quantities in the three layers, it is possible to balance the increase in thickness of the gelled layer of the U and L layers and the erosion and/or dissolution of the C layer. The increase in external surface area will compensate reduced release due to the increase in thickness of the gelled layer, thus allowing a kinetic of zero order. According to the type and proportion of swelling polymers and of active principles in the external U and L layers, a polymer could if necessary be included in the central C layer to delay the dissolution and/or erosion process.

In the case of Figure 1b the U layer consists in a mixture of a hydrophilic polymer and an active principle. On the other hand, the L layer consists in a mixture of a soluble and/or erodible polymer, or a soluble excipient, in which an active principle, the same or different from the one in the U layer, may be added.

When one of these systems comes in contact with the aqueous dissolution medium, the U layer takes up water, giving rise to a gel of increasing thickness. If a swellable hydrophilic polymer is used, the system swells. In this way, the drug will be released mainly by a diffusion mechanism, in part governed also by distension of the polymeric chains. At the same time the L layer begins to disappear by dissolution and/or erosion. The progressive disappearance of the L layer gives rise to an increase in surface area of the gelled U layer exposed to the action of the solvent, added to that due to the swelling of the U layer itself.

Reduction of release rate, due to the increase in thickness of the gelled layer of the U layer, is therefore balanced by the erosion and/or dissolution of the L layer bringing about an increase in release surface area. This allows solvent contact with that part of the surface of the U layer initially coated by the L layer. If an active principle is incorporated in the L layer, its release is controlled by the erosion and/or dissolution of the layer itself. After a certain time period, mostly related to the composition of the L layer, the complete dissolution of this layer is observed and only the U layer remains, evolving as a simple matrix.

A schematic drawing of the evolution of the system during the release period is shown in Figure 3, where

the release area increases in time as a result of the disappearance of the L layer.

The following examples illustrate some multilayer matrix systems, according to the invention, which have the typical form of a flat or biconvex double- or three-layer tablet with or without break-line, prepared by simultaneous compression or by joining two or more individually prepared layers. The dosage unit can sometimes consist of a group of monolithic systems contained in a hard gelatin capsule.

Example 1

Preparation of a three-layer matrix system containing 100 mg of Atenolol subdivided between the U and L layers.

a) Preparation of Granulate for the U and L Layers

400 g of granulate contains:

Atenolol (active principle)	100 g
Cellulose acetate phthalate	8 g
Talc	80 g
Hydroxypropyl methylcellulose	75 g
Mannitol	128 g
Magnesium stearate	4 g
Silicon dioxide	5 g

The active principle and part of the talc (50 g) were blended in a powder mixer until homogeneous mixture was obtained.

The cellulose acetate phthalate was dissolved in 560 ml of a 1:2 mixture of ethanol and acetone and used to wet the above powder mixture. The mass was then granulated on a 800 μ screen, dried and calibrated through a 600 μ screen. The granulate thus obtained was mixed with the other powders, previously blended.

b) Preparation of Granulate for the C Layer

Four different mixtures were prepared, three of which containing increasing concentrations of a soluble polymer (hydroxyethylcellulose) and inert excipients.

200 g of granulate contains:

Type I

Spray-dried lactose	176 g
Magnesium stearate	2 g
Talc	22 g

In this case the powders are blended to obtain a homogeneous mixture.

Type II

Spray-dried lactose	176 g
Hydroxyethylcellulose	5 g
Talc	15 g
Magnesium stearate	4 g

In this case, the lactose, part of the talc (10 g) and the hydroxyethylcellulose are blended to homogeneity. The mixture is then wetted with water and granulated on a 800 μ screen. After drying the granulate is calibrated through a 600 μ screen and then mixed with the magnesium stearate and the remaining talc (5 g).

Type III

Spray-dried lactose	171 g
Hydroxyethylcellulose	10 g
Talc	15 g
Magnesium stearate	4 g

The same procedure is used as for Type II

Type IV

Spray-dried lactose	161 g
Hydroxyethylcellulose	20 g
Talc	15 g
Magnesium stearate	4 g

The same procedure is used as for type II

c) Preparation of Three-layer Tablets

The systems described in this example were obtained using a reciprocating tableting machine (Model EKO, Korsch, Berlin) and flat punches of 11.3

mm diameter for the simultaneous compression of three layers, respectively:

- L layer consisting of 200 mg of granulate as point a) above;
- C layer consisting of 200 mg of mixture as point b) above;
- U layer consisting of 200 mg of granulate as point a) above.

By varying the C layer (types I, II, III and IV), different release profiles were obtained: it was noted that the optimum polymer concentration in the C layer, to obtain a kinetic of the zero order, is that of case III.

As reference, simple matrices were prepared by compression, consisting of a single layer of 400 mg of the granulate as point a), therefore equivalent to the whole of the U and L layers of the three-layer matrix (type O).

d) In Vitro Active Principle Release Tests

In vitro tests were carried out on the three-layer systems and on the one-layer matrices used as reference. The dissolution apparatus described in US Pharmacopoeia XXII (711), pages 1578-9, Apparatus 2, was used for these determinations, with a paddle rotation speed of 125 rpm. A square screen (l = 33 mm; openings 1.25 mm) was placed on the bottom of the dissolution vessel to prevent the tablets from sticking to it. Distilled water at 37°C was used as dissolution medium.

The amount of active principle released was spectrophotometrically determined at 224.5 nm in a 1 mm continuous flow cell, at 5-10-15-30-45-60-90 minutes and then every 30 minutes until complete release of the active principle.

Results of the in vitro tests are shown in Figure 4.

The release profiles of the one-layer reference tablets and those of the tablets according to this invention are clearly different. This agrees with the release control function played by the central C layer.

For the type O, one-layer matrices, equivalent to the whole of the U and L layers in the three-layer matrices, dissolution rate decreases since the early release phases, as expected. Actually the overcoming of this drawback is the target of this present invention.

For the type I, three-layer matrices according to this present invention, in which the soluble C layer does not contain polymers, the release profile has a sigmoid shape owing to a too fast detachment of the U and L layers: as the increase in release surface area is sudden, the release rate increases too quickly.

Using 2.5% of hydroxyethylcellulose (type II) in the C layer, a linearization of the release profile can already be observed. This linearization is almost total in the case of type III, 5% of polymer being incorporated into the C layer: the release rate is practically constant almost till to the end of the release process.

With a further increase of the polymer content in the C layer, the disappearance of the C layer is delayed to such an extent as to obtain a release profile comparable to that of type O.

Example 2

Preparation of three-layer matrix systems containing 400 mg of Trapidil subdivided between the U and L layers.

a) Preparation of Granulate for the U and L Layers

550 g of granulate contains:

Trapidil (active principle)	400 g
Hydroxypropyl methylcellulose	125 g
Carboxymethylcellulose sodium	20 g
Magnesium stearate	5 g

The first three components were blended in a powder mixer until homogeneous mixture.

A 1:1 mixture of ethanol and water was prepared and used to wet the powder mixture. The mass was granulated on a 800 μ screen, dried and then calibrated through a 600 μ screen. The obtained granulate was then mixed with the magnesium stearate.

b) Preparation of a Mixture for the C Layer

Type I

200 g of mixture contains:

Spray-dried lactose	176 g
Magnesium stearate	2 g
Talc	22 g

Simple mixing is carried out to obtain a homogeneous mixture.

c) Preparation of Three-Layer Tablets

The systems described in this example were obtained using a reciprocating tableting machine (Model EKO, Korsch, Berlin) and concave punches of 12 mm diameter for the simultaneous compression of three layers, respectively:

- L layer consisting of 275 mg of granulate as point a);
- C layer consisting of 200 mg of mixture as point b);

U layer consisting of 275 mg of granulate as point a).

As reference, simple matrices were prepared by compression, consisting of a single layer of 550 mg of granulate as point a), therefore equivalent to the whole of the U and L layers of the three-layer matrix (type O).

d) In Vitro Active Principle Release Tests

In vitro tests were carried out on the three-layer systems and on the one-layer matrices used as reference. The dissolution apparatus described in US Pharmacopoeia XXII (711), pages 1578-9, Apparatus 2, was used for these determinations, with a paddle rotation speed of 125 rpm. A square screen (l = 33 mm; openings 1.25 mm) was placed on the bottom of the dissolution vessel to prevent the tablets from sticking to it. Distilled water at 37°C was used as dissolution medium.

The amount of active principle released was spectrophotometrically determined at 271 nm in a 1 mm continuous flow cell, at 5-10-15-30-45-60-90 minutes and then every 30 minutes until complete release of the active principle.

Results of the in vitro tests are shown in Figure 5.

The release profiles of the one-layer reference tablets and those of the tablets according to this invention are clearly different. This agrees with the release control function played by the central C layer.

For the type O, reference matrices, dissolution rate decreases in time, as expected. Actually the overcoming of this drawback is the target of this present invention.

In particular, a quite high initial dissolution rate is observed which decreases progressively.

For the type I, three-layer matrices according to this present invention, the release profile is quite linear, owing to the fast disappearance of the C layer.

Example 3

Preparation of monolithic two-layer systems containing 100 mg of Atenolol in the U layer.

a) Preparation of Granulate for the U Layer

500 g of granulate contains:

Atenolol (active principle)	100 g
Cellulose acetate phthalate	8 g
Talc	80 g
Hydroxypropyl methylcellulose	75 g
Mannitol	128 g
Magnesium stearate	4 g
Silicon dioxide	5 g

The active principle and part of the talc (50 g) were blended in a powder mixer until homogeneous mixture.

A solution of the cellulose acetate phthalate was prepared in 560 ml of a 1:2 mixture of ethanol and acetone and used to wet the above powder mixture. The mass was then granulated on a 800 μ screen, dried and calibrated through a 600 μ screen. The obtained granulate was then mixed with the other constituents, previously blended.

b) Preparation of Granulate for the L Layer

(Type I)

200 g of granulate contains:

Spray-dried lactose	171 g
Hydroxyethylcellulose	10 g
Talc	15 g
Magnesium stearate	4 g

The lactose, part of the talc (10 g) and the hydroxyethylcellulose were blended to homogeneity. The powder mixture was wetted with water, granulated on a 800 μ screen, dried and then calibrated through a 600 μ screen. The obtained granulate was mixed with the magnesium stearate and the remaining talc (5 g).

c) Preparation of Two-Layer Tablets

The systems described in this example were obtained using a reciprocating tableting machine (Model EKO, Korsch, Berlin) and flat punches of 11.3 mm diameter for the simultaneous compression of two layers, respectively:

U layer consisting of 400 mg of granulate as point a);

L layer consisting of 200 mg of mixture as point b).

A reference, simple matrices were prepared by compression, consisting of a single layer of 400 mg of

granulate as point a), therefore equivalent to the U layer of the two-layer matrix (type O).

d) In Vitro Active Principle Release Tests

In vitro tests were carried out on the two-layer systems and on the one-layer matrices used as reference. The dissolution apparatus described in US Pharmacopoeia XXII (711), pages 1578-9, Apparatus 2, was used for these determinations, with a paddle rotation speed of 125 rpm. A square screen (l = 33 mm; openings 1.25 mm) was placed on the bottom of the dissolution vessel to prevent the tablets from sticking to it. Distilled water at 37°C was used as dissolution medium.

The amount of active principle released was spectrophotometrically determined at 224.4 nm in a 1 mm continuous flow cell, at 5-10-15-30-45-60-90 minutes and then every 30 minutes until complete release of the active principle.

Results of the in vitro tests are shown in Figure 6.

The release profiles of the one-layer reference matrices and those of the two-layer systems according to this invention are clearly different. This agrees with the release control function played by the L layer. The gradual disappearance of the L layer in the type I matrices, in fact allows a gradual increase of the releasing surface area such as to achieve a constant release rate, unlike what is observed in the case of the reference one-layer matrices (type O).

Claims

1. Monolithic system for the controlled release of active principles, consisting of:

- a) at least one swelling layer containing one or more active principles in a matrix of hydrophilic swellable polymers;
- b) at least one erodible and/or soluble layer consisting of water soluble excipients and/or polymers, possibly containing one or more active principles, the same as or different from those present in the a) layer, the said erodible and/or soluble layer being in contact with the swelling layer(s) a).

2. System according to claim 1 consisting of two external swelling layers separated by an interposed soluble layer.

3. System according to claim 1 consisting of a swelling layer adjacent to an erodible and/or soluble layer.

4. System according to one of the preceding claims in which the hydrophilic, swellable polymers of the a) layer are selected from: methylcellulose, carboxymethylcellulose, crosslinked carboxymethylcellu-

lose sodium, crosslinked hydroxypropylcellulose, high, medium or low molecular weight hydroxypropylmethylcellulose, carboxymethyl starch, polymethacrylate, polyvinylpyrrolidone (crosslinked or not), high medium or low molecular weight polyvinyl alcohols, polyoxyethylene glycols, potassium methacrylate-divinylbenzene copolymer and their mixtures.

5. System according to claim 4 in which the hydrophilic polymers are present in proportions between 5% and 70% by weight.

6. System according to any of the claims 1 to 3 in which the water soluble polymers are selected from hydroxyethylcellulose, carboxymethylcellulose, alginates, albumin, soluble starch and gelatin.

7. System according to claim 6 in which the water soluble polymers are present in proportions up to 20% by weight.

8. System according to any of the preceding claims, represented by a plain or biconvex tablet, with or without break-line.

9. System according to any of the preceding claims suitable for oral administration.

10. System according to any of the preceding claims in which the constituting layers contain one or more ameliorative excipients selected from spray-dried lactose, mannitol or other polyalcohols, talc, magnesium stearate or other lubricants.

11. System according to any of the preceding claims in which the active principle is present in the swelling layers only.

12. System according to any of claims 1 to 10 in which the active principle is present also in the soluble and/or erodible layer.

13. System according to claims 11 or 12, containing a single active principle.

14. System according to claims 11 or 12, containing two or more active principles, different for each layer.

15. System according to any of the preceding claims obtained by simultaneous compression of the layers or by joining two or three separately prepared layers.

16. Pharmaceutical compositions in which the dosage unit consists of a group of systems according to the preceding claims, introduced into a suitable con-

tainer, such as gelatin capsule.

Patentansprüche

1. Monolithisches System für die kontrollierte Freisetzung von Wirkstoffen (aktiven Prinzipien), das besteht aus:

a) mindestens einer quellbaren Schicht (Quellungsschicht), die einen oder mehr Wirkstoffe (aktive Prinzipien) in einer Matrix aus hydrophilen quellbaren Polymeren enthält; und
b) mindestens einer erodierbaren und/oder löslichen Schicht, bestehend aus wasserlöslichen Exzipienten und/oder Polymeren, die möglicherweise ein oder mehr Wirkstoffe (aktive Prinzipien) enthält, die gleich oder verschieden sind von denjenigen, die in der Schicht (a) enthalten sind, wobei die genannte erodierbare und/oder lösliche Schicht mit der(den) quellbaren Schicht(en) (a) in Kontakt steht.

2. System nach Anspruch 1, das aus zwei außenliegenden quellbaren Schichten besteht, die durch eine dazwischenliegende lösliche Schicht voneinander getrennt sind.

3. System nach Anspruch 1, das besteht aus einer quellbaren Schicht, die an eine erodierbare und/oder lösliche Schicht angrenzt.

4. System nach einem der vorhergehenden Ansprüche, bei dem die hydrophilen, quellbaren Polymeren der Schicht (a) ausgewählt werden aus Methylcellulose, Carboxymethylcellulose, vernetzter Natriumcarboxymethylcellulose, vernetzter Hydroxypropylcellulose, Hydroxypropylmethylcellulose mit hohem, mittlerem oder niedrigem Molekulargewicht, Carboxymethylstärke, Polymethacrylat (vernetzt oder nicht-vernetzt), Polyvinylpyrrolidon, Polyvinylalkoholen mit hohem, mittlerem oder niedrigem Molekulargewicht, Polyoxyethylenglycolen, Kaliummethacrylat/Divinylbenzol-Copolymer und Mischungen davon.

5. System nach Anspruch 4, in dem die hydrophilen Polymeren in Mengenanteilen zwischen 5 und 70 Gew.-% vorliegen.

6. System nach einem der Ansprüche 1 bis 3, bei dem die wasserlöslichen Polymeren ausgewählt werden aus Hydroxyethylcellulose, Carboxymethylcellulose, Alginaten, Albumin, löslicher Stärke und Gelatine.

7. System nach Anspruch 6, bei dem die wasserlöslichen Polymeren in Mengenanteilen von bis zu 20 Gew.-% vorliegen.

8. System nach einem der vorhergehenden Ansprüche, dargestellt durch eine ebene (flache) oder bikonvexe Tablette mit oder ohne Bruchlini.

9. System nach einem der vorhergehenden Ansprüche, das für die orale Verabreichung geeignet ist.

10. System nach einem der vorhergehenden Ansprüche, bei dem die es aufbauenden Schichten einen oder mehr Verbesserungs-Exzipienten, ausgewählt aus sprühtrockneter Lactose, Mannit oder anderen Polyalkoholen, Talk, Magnesiumstearat oder anderen Gleit- bzw. Schmiermitteln, enthalten.

11. System nach einem der vorhergehenden Ansprüche, bei dem der Wirkstoff (das aktive Prinzip) nur in den quellbaren Schichten vorliegt.

12. System nach einem der Ansprüche 1 bis 10, bei dem der Wirkstoff (das aktive Prinzip) auch in der löslichen und/oder erodierbaren Schicht vorliegt.

13. System nach Anspruch 11 oder 12, das einen einzelnen Wirkstoff (aktives Prinzip) enthält.

14. System nach Anspruch 11 oder 12, das zwei oder mehr Wirkstoffe (aktive Prinzipien) enthält, die für jede Schicht verschieden sind.

15. System nach einem der vorhergehenden Ansprüche, wie es erhalten wird durch gleichzeitiges Pressen der Schichten oder durch Vereinigen von zwei oder drei getrennt hergestellten Schichten.

16. Pharmazeutische Zusammensetzungen, bei denen die Dosierungseinheit besteht aus einer Gruppe von Systemen nach den vorhergehenden Ansprüchen, die in einen geeigneten Behälter, beispielsweise in eine Gelatine kapsel, eingeführt worden sind.

Revendications

1. Système monolithique pour la libération contrôlée de principes actifs, constitué de :

a) au moins une couche gonflable contenant un ou plusieurs principes actifs dans une matrice de polymères gonflables hydrophiles ;
b) au moins une couche pouvant s'éroder et/ou soluble, constituée d'excipients et/ou de polymères hydrosolubles, contenant éventuellement un ou plusieurs principes actifs, identiques ou différents de ceux présents dans la couche a), ladite couche pouvant s'éroder et/ou soluble étant en contact avec la ou les couches gonflables a).

2. Système selon la revendication 1, constitué de deux couches gonflables externes séparées par une couche soluble intercalée.
3. Système selon la revendication 1, constitué d'une couche gonflable adjacente à une couche pouvant s'éroder et/ou soluble.
4. Système selon l'une quelconque des revendications précédentes, dans lequel les polymères gonflables, hydrophiles de la couche a) sont choisis parmi : méthylcellulose, carboxyméthylcellulose, carboxyméthylcellulose réticulée sodique, hydroxypropylméthylcellulose de poids moléculaire élevé, moyen ou faible, carboxyméthylamidon, polyméthacrylate, polyvinylpyrrolidone (réticulée ou non), alcools polyvinyliques de poids moléculaire élevé, moyen ou faible, polyoxyéthylène glycols, copolymère méthacrylate de potassium-divinylbenzène et leurs mélanges.
5. Système selon la revendication 4, dans lequel les polymères hydrophiles sont présents dans des proportions comprises entre 5% et 70% en poids.
6. Système selon l'une quelconque des revendications 1 à 3, dans lequel les polymères hydrosolubles sont choisis parmi l'hydroxyéthylcellulose, la carboxyméthylcellulose, les alginates, l'albumine, l'amidon soluble et la gélatine.
7. Système selon la revendication 6, dans lequel les polymères hydrosolubles sont présents dans des proportions allant jusqu'à 20% en poids.
8. Système selon l'une quelconque des revendications précédentes, représenté par un comprimé plat ou biconvexe, avec ou sans ligne de rupture.
9. Système selon l'une quelconque des revendications précédentes, convenant à l'administration orale.
10. Système selon l'une quelconque des revendications précédentes, dont les couches constituantes contiennent un ou plusieurs excipients améliorateurs choisis parmi le lactose pulvérisé à sec, le mannitol ou d'autres polyols, le talc, le stéarate de magnésium ou d'autres lubrifiants.
11. Système selon l'une quelconque des revendications précédentes, dans lequel le principe actif n'est présent que dans les couches gonflables.
12. Système selon l'un quelconque des revendications 1 à 10, dans lequel le principe actif est également présent dans la couche soluble et/ou pouvant s'éroder.
13. Système selon la revendication 11 ou 12, contenant un seul principe actif.
14. Système selon la revendication 11 ou 12, contenant deux principes actifs ou plus, différents pour chacune des couches.
15. Système selon l'une quelconque des revendications précédentes, obtenu par compression simultanée des couches ou en joignant deux ou trois couches préparées séparément.
16. Compositions pharmaceutiques, dans lesquelles l'unité posologique est constituée d'un groupe de systèmes selon les revendications précédentes, introduit dans un récipient approprié, tel qu'une capsule de gélatine.




FIGURE 1




FIGURE 2




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6